Risk factors for progression of structural lung disease in school-age children with cystic fibrosis.
Chest CT
Cystic fibrosis
FEV(1)
Pseudomonas aeruginosa
Structural lung disease
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
20
05
2019
revised:
14
10
2019
accepted:
14
10
2019
pubmed:
2
11
2019
medline:
21
10
2021
entrez:
2
11
2019
Statut:
ppublish
Résumé
Computed tomography (CT) is used to monitor progression of structural lung disease (SLD) in children with cystic fibrosis (CF). Our goals were to identify the risk factors for the annual progression of SLD and the impacts of airway pathogens on SLD. Seventy-five school-aged children diagnosed with CF underwent 200 CT scans at Gothenburg CF Centre in the period 2003-2015. SLD was evaluated with a quantitative scoring system. Mixed models were used to calculate the yearly progression rates of SLD and FEV The yearly mean progression (95% CI) rates for total disease (%Dis), bronchiectasis (%Be), and FEV Intermittent respiratory infections with P aeruginosa were associated with significant SLD but no change in FEV
Sections du résumé
BACKGROUND
Computed tomography (CT) is used to monitor progression of structural lung disease (SLD) in children with cystic fibrosis (CF). Our goals were to identify the risk factors for the annual progression of SLD and the impacts of airway pathogens on SLD.
METHOD
Seventy-five school-aged children diagnosed with CF underwent 200 CT scans at Gothenburg CF Centre in the period 2003-2015. SLD was evaluated with a quantitative scoring system. Mixed models were used to calculate the yearly progression rates of SLD and FEV
RESULTS
The yearly mean progression (95% CI) rates for total disease (%Dis), bronchiectasis (%Be), and FEV
CONCLUSION
Intermittent respiratory infections with P aeruginosa were associated with significant SLD but no change in FEV
Identifiants
pubmed: 31672554
pii: S1569-1993(19)30929-4
doi: 10.1016/j.jcf.2019.10.014
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
910-916Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Tiddens has a patent licensed for the PRAGMA-CF scoring system. He is heading the Erasmus MC-Sophia Children's Hospital core laboratory Lung Analysis. FLUIDDA has developed computational fluid dynamic modeling based on chest-CTs obtained from Erasmus MC-Sophia for which royalties are received by Sophia Research BV. All financial aspects for the grants are handled by Sophia Research BV.